Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022
- PMID: 36692840
- DOI: 10.1158/1078-0432.CCR-22-3399
Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022
Abstract
A recent randomized phase II study of sunitinib or cediranib in alveolar soft part sarcoma established benchmark activity for commonly used tyrosine kinase inhibitors (TKI). The impact of TKIs, as well as immunotherapy, has redefined treatment paradigms and greatly improved outcomes for this historically dismal sarcoma. See related article by Nguyen et al., p. 1200.
©2023 American Association for Cancer Research.
Comment in
-
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.Clin Cancer Res. 2023 Apr 3;29(7):1200-1208. doi: 10.1158/1078-0432.CCR-22-2145. Clin Cancer Res. 2023. PMID: 36302173 Free PMC article.
Comment on
-
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.Clin Cancer Res. 2023 Apr 3;29(7):1200-1208. doi: 10.1158/1078-0432.CCR-22-2145. Clin Cancer Res. 2023. PMID: 36302173 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
